INTRODUCTION {#s1}
============

Apurinic/apyrimidinic endonuclease/Ref-1 (APE1), the mammalian ortholog of *Escherichia coli* Xth, is a multifunctional protein with both DNA base excision repair (BER) and cell oxidative stress response capabilities and plays a key role in the incision of AP sites and the generation of 3'OH in basic reactions of the BER pathway \[[@R1]\]. Reflecting its other name of redox effector factor 1 (Ref-1), it reacts to different cellular stress by regulating the activity of various transcription factors, such as early growth response protein-1 (Egr-1), nuclear factor-κB (NF-κB), p53, hypoxia inducible factor-1α (HIF-1a) and activator protein-1 (AP-1) \[[@R2]\], which are involved in various cellular processes, including survival, cell cycle, cell growth, stem cell properties and inflammatory pathways. The main mechanism by which APE1/Ref-1 controls transcriptional factor activities is through reducing cysteine residues, thereby activating their DNA-binding activity \[[@R3], [@R4]\]. Thus, APE1 is thought to be the hub protein of cellular regulation.

Unsurprisingly, APE1 has been found to be involved in various human diseases including cancer, cardiovascular disease, and neurodegenerative diseases. Up-regulated or activated APE1 has been identified in several tumors, such as non-small cell lung cancer (NSCLC), gastric cancer, esophageal squamous cell carcinoma (ESCC) and bladder cancers \[[@R5]--[@R8]\], and is associated with a worse prognosis. APE1 levels are also reported to be a predictive marker for sensitivity to chemotherapy in NSCLC patients \[[@R9]\]. Moreover, the inhibition of APE1 can significantly enhance the anti-tumor effects of chemotherapy in cancers \[[@R10]\]. Thus, APE1 appears to be a very promising therapeutic target for cancer patients.

However, in some types of cancer, including hepatocellular carcinoma (HCC) and breast cancer, it has the opposite effect \[[@R11]--[@R13]\], and high levels of APE1 are favorable for the prognosis of patients. Some contradictory results are reported in glioma, NSCLC and gastric tumors, showing the complex role of APE1 in tumors \[[@R14]\]. What is more, cytoplasmic and mitochondrial localization of APE1 has been observed independently by several groups, which is unexpected for APE1, presumably a nuclear protein \[[@R15]\]. To the best of our knowledge, APE1 is not activated in the cytoplasm. Thus, it is necessary to investigate the prognostic value of APE1 overexpression in different solid tumors.

In this study, we found fifteen qualifying studies of the prognostic role of APE1 in eight types of tumors. A systematic meta-analysis was conducted to evaluate the prognostic role of APE1 in solid tumors, providing a novel reference for further therapeutic studies of APE1.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

A total of 80 potentially relevant publications were retrieved after the initial database searches, and 15 eligible studies were finally included in the study, comprising 1574 patients for analysis. A flow diagram of the study selection process is presented in Figure [1](#F1){ref-type="fig"}. The main characteristics of the 15 studies are reported in Table [1](#T1){ref-type="table"}. The studies were conducted in 4 countries (China, Korea, Italy and the UK) and published from 2007 to 2016. Cancer types of the patients included lung carcinoma, ESCC, gastric carcinoma, ovarian carcinoma, HCC, locally advanced rectal cancer, breast cancer, glioma and osteosarcoma \[[@R6], [@R9]--[@R14], [@R16]--[@R23]\]. APE1 expression was evaluated by IHC in all 15 studies in our meta-analysis. All studies examined the association between APE1 positive expression and OS. Among them, seven studies reported that APE1 expression was detected in both the nucleus and cytoplasm, while five studies found only nuclear expression, and three studies found only cytoplasm expression. High expression of APE1 predicts a worse prognosis in 12 studies, while a better prognosis is observed in 3 studies. These studies obtained quality assessment scores ranging from 5 to 8.

![Flow diagram of the literature search strategy in the meta-analysis](oncotarget-08-59720-g001){#F1}

###### Main characteristic and results of the 15 included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study     Year   Tumor\                         Patient source   PN    Stages                     Methods   HIGH   Low   Subcellular location\   Median follow up (Months)   Out-come   12-month-SR(H)   12-month-SR(L)   36-month-SR(H)   36-month-SR(L)   HR      95% High   95% Low   Result\    QA
                   type                                                                                                    (N/C)                                                                                                                                                           (F or U)   
  --------- ------ ------------------------------ ---------------- ----- -------------------------- --------- ------ ----- ----------------------- --------------------------- ---------- ---------------- ---------------- ---------------- ---------------- ------- ---------- --------- ---------- ----
  Zhang     2016   Lung                           China            172   III-IV                     IHC       126    46    N+C                     11(1-43)                    OS         48.66            70.47            9.06             9.06             1.19    1.74       0.81      U          8

  Wei       2016   Lung                           China            78    II-IV                      IHC       56     22    N+C                     NA                          OS         57.75            76.96            12.29            15.27            1.31    2.34       0.73      U          7

  Wu        2010   Lung                           China(Taiwan)    100   I-III                      IHC       49     51    C                       36.1(3.3--68.9)             OS         NA               NA               96.72            96.7             2.243   3.855      1.305     U          7

  Woo       2014   Breast                         Korea            239   I-III                      IHC       177    62    N                       61                          OS         98               100              27.92            67.36            0.78    2.39       0.25      NA         8

  Wang      2009   Lung                           China            103   I-III                      IHC       76     27    N+C                     NA                          OS         94.75            99               NA               NA               2.47    6.02       1.01      U          6

  Han       2014   ESCC                           China            93    I-IV                       IHC       69     24    N                       35(0.13-52)                 OS         NA               NA               26.56            47.99            1.328   2.777      0.635     NA         7

  Wei       2016   Gastric                        China            65    I-IV                       IHC       50     15    N                       28.5                        OS         90.2             99.8             32.95            50.51            2.57    6.18       1.07      U          7

  Qing      2015   Gastric                        China            107   NA                         IHC       93     14    N+C                     42                          OS         84.01            92.53            43.2967          28.5714          1.42    3.24       0.62      U          7

  Perry     2014   Glioma                         UK               60    NA                         IHC       35     25    N                       12.8(0.23-111.7)            OS         78.02            62.6             9.39             35.79            0.53    1.02       0.28      F          6

  Ren       2014   Osteo-\                        China            80    I-III (Enneking staging)   IHC       55     25    N+C                     NA                          OS         61.17            83.69            76.7176          92.7439          1.77    2.9        1.07      U          7
                   sarcoma                                                                                                                                                                                                                                                                            

  Kim       2012   LARC                           Korea            83    I-III                      IHC       32     51    C                       82(18-114)                  OS         100              100              57.5713          62.8788          2.05    4.67       0.9       NA         7

  Londero   2014   Ovarian\                       Italy            73    I-IV(FIGO)                 IHC       37     36    N                       NA                          OS         85.61            93.94            NA               NA               1.74    3.41       0.88      U          7
                   cancer                                                                                                                                                                                                                                                                             

  Maso      2007   Hepatocellular carcinoma       Italy            47    G1-G4                      IHC       NA     NA    C                       NA                          OS         NA               NA               NA               NA               2.2     4.3        1.1       U          5

  Kan       2015   Hepatocellular carcinoma       China            128   I-IV                       IHC       86     42    N+C                     10                          OS         NA               NA               68.35            78.25            0.771   1.13       0.526     NA         6

  Hsia      2016   Oral squamous cell carcinoma   China(Taiwan)    146   I-IV                       IHC       77     69    N                       NA                          OS         83.44            91.96            9.06             9.06             1.825   3.287      1.014     U          7
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: Not applicable

LARC: Locally advanced rectal cancer

PN: patient number

Subcellular location (N/C): N: nucleus; C: Cytoplasm

M/U M: Multivariate; U: Univariate

Result: F: Favorable; U: Unfavorable

QA: quality assessment

12/36-month-SR(H): 12/36-month survival rats (High APE1 level); 12/36-month-SR(L): 12/36-month survival rates (Low APE1 level) HR: hazard ratio

Meta-analysis results {#s2_2}
---------------------

The correlation between APE1 expression and OS was calculated, and heterogeneity was found among the studies (I^2^ = 53%, *P* = 0.007); therefore, a random model was applied to calculate the pooled HR and its 95% CI. The combined analysis of 15 studies showed that APE1 overexpression was significantly correlated with shorter OS in solid tumors (HR 1.44, 95% CI 1.13--1.83, *P* = 0.003) (Figure [2A](#F2){ref-type="fig"}).

![Forest plot (**A**) of the hazard ratio for the association of APE1 levels and OS; Begg\'s funnel plots of publication bias (**B**) for the meta-analysis of the hazard ratio for the association of APE1 levels and OS.](oncotarget-08-59720-g002){#F2}

In the subgroup analysis, nuclear-expressed APE1 in 12 studies was correlated with shorter OS (HR 1.30, 95% CI 1.00--1.68, *P* = 0.05, Figure [3A](#F3){ref-type="fig"}). In the three studies finding expression in only the cytoplasm, APE1 overexpression also showed significant association with shorter OS (HR 2.19, 95% CI 1.50--3.21, *P* \< 0.0001, Figure [3C](#F3){ref-type="fig"}).

![Subgroup analysis of APE1 nuclear/cytoplasmic expression and OS\
Forest plot (**A**) of the hazard ratio for the association of nuclear-expressed APE1 levels and OS; Begg\'s funnel plots of publication bias (**B**) for meta-analysis of OS of high and low nuclear-expressed APE1; forest plot (**C**) of the hazard ratio for the association of cytoplasm-expressed APE1 levels and OS; Begg\'s funnel plots of publication bias (**D**) for meta-analysis of OS of high and low cytoplasm-expressed APE1.](oncotarget-08-59720-g003){#F3}

To further analyze the effects of APE1 on survival in tumor patients, the one-year and three-year survival rates were extracted from 10 studies. We investigated the effects of APE1 expression on short and long term survival in tumor patients. Patients with high APE1 expression had lower 12-month survival rates than those with low APE1 levels (HR 2.00 95% CI 1.30--3.00, *P* = 0.0009, Figure [4A](#F4){ref-type="fig"}). Similarly, overexpression of APE1 was correlated with a lower 36-month survival rate among cancer patients (HR 1.84 95%CI 1.19--2.84, *P* = 0.006, Figure [4C](#F4){ref-type="fig"}).

![Subgroup analysis of 1-year and 3-year survival rates and APE1 expression\
Forest plot (**A**) of the hazard ratio for the association of APE1 levels and 1-year survival rate; Begg\'s funnel plots of publication bias (**B**) for meta-analysis of 1-year survival rate of high and low APE1 expression; forest plot (**C**) of the hazard ratio for the association of APE1 levels and 3-year OS; Begg\'s funnel plots of publication bias (**D**) for meta-analysis of 3-year survival rates of high and low APE1 expression.](oncotarget-08-59720-g004){#F4}

Publication bias {#s2_3}
----------------

Funnel plots were performed to assess the publication bias in this meta-analysis. Publication bias can be observed in only the one-year survival rate analysis; other major analyses did not reveal obvious evidence of asymmetry (Figures [2B](#F2){ref-type="fig"}, [3B, 3D](#F3){ref-type="fig"}, [4B, 4D](#F4){ref-type="fig"}).

DISCUSSION {#s3}
==========

In this study, we meta-analyzed the prognostic role of APE1 in different types of solid tumors. The results show that overexpression of APE1 acted as an unfavorable prognostic factor for solid tumors.

Dysregulation of APE1/Ref-1 has been reported to be associated with cancers for 20 years. Both nuclear and cytoplasmic expression levels of APE1 can be altered in cancers, but it is still unclear how nuclear and cytoplasmic expression of APE1 specifically alter and affect different cancers \[[@R22], [@R23]\]. Most studies propose that high APE1 is associated with poor prognosis. However, some manuscripts noted that low APE1 was independently associated with poor prognosis \[[@R12]\]. Thus, a meta-analysis of the prognostic role of APE1 is very important. Based on our meta-analysis, regardless of its subcellular location, the expression of APE1 is prognostically significant. To explore the differences in nuclear and cytoplasmic APE1 expression, we continued the subgroup analysis by dividing the included papers into nuclear and cytoplasmic groups and found that both types of APE1 expression are important indicators of poor prognosis. This result not only implies the pleiotropic function of APE1 in mammalian cells but also calls for further research of cytoplasmic APE1. Although its cooperation with AP1, EGR1 and other onco-transcription factors has been discovered, its functions in the cytoplasm remain largely unknown. One explanation of its cytoplasmic accumulation is that Cys93 and Cys310 of APE1 can be S-nitrosated when stimulated by nitric oxide, leading to the cytoplasmic relocalization of the protein \[[@R24]\]. In lung cancer, it is reported that nuclear factor-kappa B is activated by cytoplasmic APE1 \[[@R21], [@R25]\]. Our meta-analysis results showed more evidence for the clinical significance of cytoplasmic APE1.

We noticed that there were 3 studies demonstrating a better prognosis based on APE1 overexpression in breast cancer, glioma and HCC. However, we found that in the breast cancer paper, there was no significant difference in OS rates between the APE1 high-level expression group and the APE1 low-level expression group (*P* = 0.294). In the HCC paper, the authors suggested that the correlation of APE1 expression with P53 and PD-L1 protein levels might account for the better prognosis, but the *p* value was 0.182, which failed to reach statistical significance. What is more, some recent transcriptional and basic studies of APE1 in hepatocellular carcinoma identified it as an oncogene \[[@R26], [@R27]\]. Therefore, the better prognosis could be a result of heterogeneity of tumor cells and samples used in the HCC paper. Regarding the glioma report, the authors speculated that APE1 operates in conjunction with other DNA repair molecules, such as NBN, PMS2, MGMT and PTEN, to influence biological and clinical outcomes in glioma. All these findings suggest that more studies of APE1 in these types of tumors are necessary.

There are some limitations of this meta-analysis. First, the number of included studies is small, and some important tumors, including bladder, renal cell and prostate cancers, have yet to be explored. More studies are needed to reveal the role that APE1 plays in these kinds of tumors. Additionally, the cutoff values used to define high and low APE1 levels in the included studies varied, which increased the heterogeneity of our meta-analysis study. ELISA-based serum detection of APE1 levels might be a good approach in the future. Finally, although obvious publication bias was not observed in our meta-analysis, potential bias might still exist since positive results were more likely to be published.

In conclusion, we demonstrated that elevated expression of APE1 detected by IHC is significantly associated with poor survival in numerous types of cancer. APE1 could be a potential biomarker for predicting prognosis in patients with solid tumors.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

A comprehensive literature search for studies on the prognostic effects of APE1 expression in solid tumor patients was conducted. The keywords used for the search were "cancer", "carcinoma", "apurinic/apyrimidinic endonuclease-1", "APE1", "HAP1", "prognosis", and "survival" (variably combined). The literature searches were performed on Pubmed, Web of Knowledge and Embase platforms The last search was conducted on 6 January 2017.

Study inclusion/exclusion criteria {#s4_2}
----------------------------------

All of the included studies in this manuscript met the following requirements: (a) published studies contained the measurement of APE1 expression in the patients with any type of adult carcinoma; (b) overall survival was included as an outcome; (c) APE1 expression was assessed by immunohistochemistry; (d) studies were published within 10 years, from 2007 to 2017; (e) studies reported hazard ratio (HR) estimates with 95% confidence intervals or the HR with 95% CI could be calculated from Kaplan-Meier survival curves; (f) the literature search was limited to studies published in English.

Studies were excluded based on the following criteria: (a) review articles, case reports, duplicated studies, conference abstract or letters; (b) studies providing insufficient survival outcome data; (c) APE1 expression was evaluated using a method other than IHC. The reviewers were blinded to the authors and institutions of the studies undergoing review.

Data extraction {#s4_3}
---------------

Two independent researchers, Chun-Ling Yuan and Yan Lin, independently extracted data from all eligible publications according to the criteria shown above. The following information, including the first author\'s name, year of publication, country of origin, tumor type, number of patients, TNM stage, follow-up period, staining location, prognostic outcomes of interest, analytical method, 12-month survival rates, 36-month survival rates and HR with its 95% CI (if both univariate and multivariate analyses were performed, HRs were extracted from multivariate analyses). Engauge Digitizer 4.1 software was applied to digitize and extract data when the prognosis information was plotted only as Kaplan-Meier curves. For the extraction of 12- and 36-year survival data, some disagreements occurred between Chun-ling Yuan and Yan Lin during the digitization of survival data. We solved these by maximizing the quality of the Kaplan-Meier plots before digitization.

Quality assessment and statistical analysis {#s4_4}
-------------------------------------------

The study\'s methodology quality was assessed and scored by two independent authors (Fan He and Hui-Ni Wu) according to the Newcastle-Ottawa quality scale (Ottawa Hospital Research Institute). Each study was given a score ranging from 0 to 9 after discussion between the two authors.

The impact of APE1 overexpression on patient survival in solid tumors was estimated by the HR and its 95% CI and one- and three-year survival rates. The one- and three-year survival rates of each study were extracted from Kaplan-Meier curves. Statistical heterogeneity between studies was quantified using Cochran\'s Q test and Higgins I-squared statistic. Heterogeneity was defined as *P* \< 0.1 or I^2^ \> 50%. In the absence of statistically significant heterogeneity, a fixed effects model was selected to combine the data. Otherwise, a random-effects model was used. Publication bias was assessed by using Begg\'s funnel plot test. For all analyses, a two-sided *P* value less than 0.05 was considered statistically significant. All analyses were performed with Cochrane Review Manager version 5.3 (Cochrane Library).
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